Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,963.94 (-1.54%)
DOW   33,849.46 (-1.45%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
S&P 500   3,963.94 (-1.54%)
DOW   33,849.46 (-1.45%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
S&P 500   3,963.94 (-1.54%)
DOW   33,849.46 (-1.45%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
S&P 500   3,963.94 (-1.54%)
DOW   33,849.46 (-1.45%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
NASDAQ:IMGO

Imago BioSciences - IMGO Stock Forecast, Price & News

$35.65
-0.01 (-0.03%)
(As of 11/28/2022 12:00 AM ET)
Add
Compare
Today's Range
$35.61
$35.67
50-Day Range
$14.16
$35.66
52-Week Range
$11.56
$35.75
Volume
1.28 million shs
Average Volume
291,636 shs
Market Capitalization
$1.21 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$36.00

Imago BioSciences MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
1.0% Upside
$36.00 Price Target
Short Interest
Bearish
17.12% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.15mentions of Imago BioSciences in the last 14 days
Based on 30 Articles This Week
Insider Trading
Selling Shares
$23,379 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.93) to ($2.54) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.52 out of 5 stars

Medical Sector

1011th out of 1,040 stocks

Pharmaceutical Preparations Industry

494th out of 509 stocks

IMGO stock logo

About Imago BioSciences (NASDAQ:IMGO) Stock

Imago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Receive IMGO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Imago BioSciences and its competitors with MarketBeat's FREE daily newsletter.

IMGO Stock News Headlines

Analyst Ratings for Imago BioSciences
Expert Ratings for Imago BioSciences
What 5 Analyst Ratings Have To Say About Imago BioSciences
Imago (IMGO) Shares Surge 104% on Buyout Offer From Merck
Imago BioSciences (NASDAQ:IMGO) Downgraded by Wedbush to Neutral
Merck to Buy Imago, Shares Gain
Merck to buy Imago Biosciences for $1.35 billion
See More Headlines
Receive IMGO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Imago BioSciences and its competitors with MarketBeat's FREE daily newsletter.

IMGO Company Calendar

Last Earnings
11/10/2021
Today
11/28/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/23/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IMGO
Fax
N/A
Employees
27
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$36.00
High Stock Price Forecast
$36.00
Low Stock Price Forecast
$36.00
Forecasted Upside/Downside
+1.0%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
6 Analysts

Profitability

Net Income
$-42,310,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$6.40 per share

Miscellaneous

Free Float
28,783,000
Market Cap
$1.21 billion
Optionable
Not Optionable
Beta
1.94

Key Executives

  • Dr. Hugh Young Rienhoff Jr. (Age 69)
    M.D., CEO & Director
    Comp: $701.78k
  • Ms. Laura G. EichornMs. Laura G. Eichorn (Age 50)
    Chief Financial Officer
    Comp: $456.06k
  • Mr. Michael H. Arenberg J.D. (Age 52)
    M.B.A., Chief Operating & Bus. Officer
  • Ms. Hsiangyi Chiang (Age 55)
    Sr. VP of Fin. & Principal Accounting Officer
  • Dr. Amy E. Tapper Ph.D. (Age 51)
    Chief of Technical Operations
  • Ms. Jennifer PeppeMs. Jennifer Peppe (Age 52)
    Global Head of Clinical Operations













IMGO Stock - Frequently Asked Questions

Should I buy or sell Imago BioSciences stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Imago BioSciences in the last twelve months. There are currently 6 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" IMGO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IMGO, but not buy additional shares or sell existing shares.
View IMGO analyst ratings
or view top-rated stocks.

What is Imago BioSciences' stock price forecast for 2023?

6 Wall Street analysts have issued twelve-month price targets for Imago BioSciences' stock. Their IMGO share price forecasts range from $36.00 to $36.00. On average, they anticipate the company's share price to reach $36.00 in the next twelve months. This suggests a possible upside of 1.0% from the stock's current price.
View analysts price targets for IMGO
or view top-rated stocks among Wall Street analysts.

How have IMGO shares performed in 2022?

Imago BioSciences' stock was trading at $23.71 at the beginning of the year. Since then, IMGO shares have increased by 50.3% and is now trading at $35.63.
View the best growth stocks for 2022 here
.

When is Imago BioSciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023.
View our IMGO earnings forecast
.

How were Imago BioSciences' earnings last quarter?

Imago BioSciences, Inc. (NASDAQ:IMGO) issued its earnings results on Wednesday, November, 10th. The company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.34) by $0.10.

When did Imago BioSciences IPO?

(IMGO) raised $105 million in an initial public offering (IPO) on Friday, July 16th 2021. The company issued 7,000,000 shares at a price of $14.00-$16.00 per share.

What is Imago BioSciences' stock symbol?

Imago BioSciences trades on the NASDAQ under the ticker symbol "IMGO."

Who are Imago BioSciences' major shareholders?

Imago BioSciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (12.60%), Citadel Advisors LLC (7.29%), Price T Rowe Associates Inc. MD (5.57%), Vanguard Group Inc. (3.66%), Emerald Advisers LLC (2.53%) and State Street Corp (1.17%). Insiders that own company stock include Amy E Tapper, Jennifer Peppe and Laura G Eichorn.
View institutional ownership trends
.

How do I buy shares of Imago BioSciences?

Shares of IMGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Imago BioSciences' stock price today?

One share of IMGO stock can currently be purchased for approximately $35.63.

How much money does Imago BioSciences make?

Imago BioSciences (NASDAQ:IMGO) has a market capitalization of $1.21 billion. The company earns $-42,310,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis.

How can I contact Imago BioSciences?

Imago BioSciences' mailing address is 329 OYSTER POINT BLVD. 3RD FLOOR, SOUTH SAN FRANCISCO CA, 904080. The official website for the company is www.imagobio.com. The company can be reached via phone at 415-529-5055 or via email at laurence@gilmartinir.com.

This page (NASDAQ:IMGO) was last updated on 11/28/2022 by MarketBeat.com Staff